ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 22.05% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 11.21% |
3ABBV | ABBVIE INC | Healthcare | $520.47B | 8.55% |
4UNH | UNITEDHEALTH GROUP INC | Healthcare | $363.01B | 5.96% |
5MRK | MERCK & CO INC | Healthcare | $362.27B | 5.95% |
6TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $259.15B | 4.26% |
7AMGN | AMGEN INC | Healthcare | $252.64B | 4.15% |
8GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 3.42% |
9ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 3.05% |
10PFE | PFIZER INC | Healthcare | $164.33B | 2.70% |
11ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 2.50% |
12MDT | MEDTRONIC PLC | Healthcare | $129.18B | 2.12% |
13BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 2.09% |
14MCK | MCKESSON CORP | Healthcare | $124.35B | 2.04% |
15SYK | STRYKER CORP | Healthcare | $118.92B | 1.95% |
16HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 1.72% |
17REGN | REGENERON PHARMACEUTICALS INC | Healthcare | $98.40B | 1.62% |
18BSX | BOSTON SCIENTIFIC CORP | Healthcare | $64.07B | 1.05% |
19BDX | BECTON DICKINSON & CO | Healthcare | $58.76B | 0.97% |
20IDXX | IDEXX LABORATORIES INC | Healthcare | $54.99B | 0.90% |
21VEEV | VEEVA SYSTEMS INC | Healthcare | $48.96B | 0.80% |
22A | AGILENT TECHNOLOGIES INC | Healthcare | $48.78B | 0.80% |
23MTD | METTLER TOLEDO INTERNATIONAL INC | Healthcare | $34.43B | 0.57% |
24ZTS | ZOETIS INC | Healthcare | $33.71B | 0.55% |
25RMD | RESMED INC | Healthcare | $33.60B | 0.55% |
26ILMN | ILLUMINA INC | Healthcare | $31.68B | 0.52% |
27DXCM | DEXCOM INC | Healthcare | $30.35B | 0.50% |
28LH | LABCORP HOLDINGS INC | Healthcare | $30.23B | 0.50% |
29ROIV | ROIVANT SCIENCES LTD | Healthcare | $28.98B | 0.48% |
30WST | WEST PHARMACEUTICAL SERVICES INC | Healthcare | $28.65B | 0.47% |
31DGX | QUEST DIAGNOSTICS INC | Healthcare | $28.57B | 0.47% |
32UTHR | UNITED THERAPEUTICS CORP | Healthcare | $25.27B | 0.42% |
33STE | STERIS PLC | Healthcare | $24.61B | 0.40% |
34THC | TENET HEALTHCARE CORP | Healthcare | $22.83B | 0.37% |
35ZBH | ZIMMER BIOMET HOLDINGS INC | Healthcare | $19.79B | 0.33% |
36MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 0.30% |
37EXEL | EXELIXIS INC | Healthcare | $17.04B | 0.28% |
38BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.23B | 0.25% |
39EHC | ENCOMPASS HEALTH CORP | Healthcare | $13.82B | 0.23% |
40COO | COOPER COMPANIES INC | Healthcare | $11.83B | 0.19% |
41ALGN | ALIGN TECHNOLOGY INC | Healthcare | $11.77B | 0.19% |
42HALO | HALOZYME THERAPEUTICS INC | Healthcare | $11.48B | 0.19% |
43UHS | UNIVERSAL HEALTH SERVICES INC | Healthcare | $11.18B | 0.18% |
44DVA | DAVITA INC | Healthcare | $10.95B | 0.18% |
45PODD | INSULET CORP | Healthcare | $10.36B | 0.17% |
46HNGE | HINGE HEALTH INC | Healthcare | $9.83B | 0.16% |
47TGTX | TG THERAPEUTICS INC | Healthcare | $9.76B | 0.16% |
48HSIC | HENRY SCHEIN INC | Healthcare | $9.52B | 0.16% |
49ATR | APTARGROUP INC | Healthcare | $8.98B | 0.15% |
50HQY | HEALTHEQUITY INC | Healthcare | $8.52B | 0.14% |
51CORT | CORCEPT THERAPEUTICS INC | Healthcare | $8.07B | 0.13% |
52CHE | CHEMED CORP | Healthcare | $7.16B | 0.12% |
53TFX | TELEFLEX INC | Healthcare | $6.07B | 0.10% |
54DOCS | DOXIMITY INC | Healthcare | $5.92B | 0.10% |
55LFST | LIFESTANCE HEALTH GROUP INC | Healthcare | $5.38B | 0.09% |
56OPCH | OPTION CARE HEALTH INC | Healthcare | $4.75B | 0.08% |
57ADMA | ADMA BIOLOGICS INC | Healthcare | $2.94B | 0.05% |
58PGNY | PROGYNY INC | Healthcare | $2.69B | 0.04% |
59MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.04% |
60ZYME | ZYMEWORKS INC | Healthcare | $1.83B | 0.03% |
61CERT | CERTARA INC | Healthcare | $1.82B | 0.03% |
62INSP | INSPIRE MEDICAL SYSTEMS INC | Healthcare | $1.75B | 0.03% |
63HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.03% |
64USPH | U S PHYSICAL THERAPY INC | Healthcare | $1.47B | 0.02% |
65PCRX | PACIRA BIOSCIENCES INC | Healthcare | $1.46B | 0.02% |
66INVA | INNOVIVA INC | Healthcare | $1.35B | 0.02% |
67AMPH | AMPHASTAR PHARMACEUTICALS INC | Healthcare | $1.23B | 0.02% |
68NUTX | NUTEX HEALTH INC | Healthcare | $1.18B | 0.02% |
69IRMD | IRADIMED CORP | Healthcare | $1.09B | 0.02% |
70DCTH | DELCATH SYSTEMS INC | Healthcare | $744M | 0.01% |
71FLGT | FULGENT GENETICS INC | Healthcare | $694M | 0.01% |
72NRC | NRC HEALTH | Healthcare | $565M | 0.01% |
73ARVN | ARVINAS INC | Healthcare | $450M | 0.01% |
74PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.01% |
75VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.01% |
76INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.00% |
77FTH | FAETH THERAPEUTICS INC | Healthcare | $275M | 0.00% |
78SPOK | SPOK HOLDINGS INC | Healthcare | $243M | 0.00% |
79UTMD | UTAH MEDICAL PRODUCTS INC | Healthcare | $234M | 0.00% |
80PDEX | PRO DEX INC | Healthcare | $216M | 0.00% |
81ELMD | ELECTROMED INC | Healthcare | $204M | 0.00% |
82ANIK | ANIKA THERAPEUTICS INC | Healthcare | $185M | 0.00% |
83JYNT | JOINT CORP | Healthcare | $92M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $6.09T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 100% toward Large, 78% toward Growth. +4% unclassified (3 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 83 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 83 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 24.3% | 25.0% |
| 3 yearsp.a. | 15.7% | -9.7% |
| 5 yearsp.a. | 11.0% | 6.4% |
| 10 yearsp.a. | 13.1% | -1.0% |
| Since inceptionp.a. | 8.2% | -4.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 26.0% | 22.2% |
| 2025 | 16.3% | -26.3% |
| 2024 | 2.1% | -0.4% |
| 2023 | 2.5% | -10.1% |
| 2022 | -0.1% | 44.0% |
| 2021 | 25.7% | 53.4% |
| 2020 | 14.1% | -38.1% |
| 2019 | 19.3% | -21.9% |
| 2018 | 7.5% | 36.1% |
| 2017 | 20.8% | -26.8% |
| 2016 | -0.6% | 8.3% |
| 2015 | 6.1% | -3.0% |
| 2014 | 21.1% | -23.1% |
| 2013 | 35.7% | -13.3% |
| 2012 | 19.1% | -6.4% |
| 2011 | 9.7% | 1.4% |
| 2010 | 2.0% | -4.0% |
| 2009 | 14.5% | -5.7% |
| 2008 | -21.7% | 16.0% |
| 2007 | 6.0% | 5.1% |
| 2006 | 5.2% | -5.0% |
| 2005 | 7.9% | 7.9% |
| 2004 | 1.2% | -4.4% |
| 2003 | 15.2% | -29.3% |
| 2002 | -20.2% | 27.8% |
| 2001 | -11.7% | -6.4% |
| 2000 | 38.5% | -44.5% |
| 1999 | -6.6% | -14.4% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare NetEqFin Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a NetEqFin signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.